Diepe hersenstimulatie bij epilepsie: wat bepaalt het effect?
- Conditions
- Epilepsy
- Registration Number
- NL-OMON26754
- Lead Sponsor
- Maastricht University Medical Center+
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
•Medically refractory epilepsy
•No possibility for resective epilepsy surgery
Exclusion Criteria
•Underlying malignancies, whenever life expectancy is lower than 2 years
•Co-medication with anti-inflammatory drugs or systemic diseases with inflammation
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We use clinical response to the treatment as a primary endpoint. We will distinguish two groups: Patients with a poor response and patients with a good to excellent response.
- Secondary Outcome Measures
Name Time Method 1.The degree of electrophysiological connectivity between the ATN and the cerebral cortex as measured directly in the phase postoperatively (single measurement)<br /><br>2.The profile (increase/decrease) of inflammation parameters in peripheral blood over the 2 years after start of the treatment (thus over 4 blood samples in 2 years)<br>